Acrux Limited (ACR.AX)
AUD 0.03
(-5.71%)
AUD 0.03
(-5.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -5.8 Million AUD | -659.16% |
| 2023 | -764 Thousand AUD | 92.23% |
| 2022 | -9.83 Million AUD | 22.13% |
| 2021 | -12.62 Million AUD | -33.34% |
| 2020 | -9.47 Million AUD | -13.77% |
| 2019 | -8.32 Million AUD | 41.3% |
| 2018 | -14.18 Million AUD | -5736.21% |
| 2017 | -243 Thousand AUD | -101.87% |
| 2016 | 12.98 Million AUD | 16.63% |
| 2015 | 11.13 Million AUD | -60.21% |
| 2014 | 27.97 Million AUD | 303.84% |
| 2013 | 6.92 Million AUD | -6.29% |
| 2012 | 7.39 Million AUD | -87.07% |
| 2011 | 57.14 Million AUD | 22.76% |
| 2010 | 46.55 Million AUD | 703.34% |
| 2009 | -7.71 Million AUD | -53.52% |
| 2008 | -5.02 Million AUD | 36.06% |
| 2007 | -7.86 Million AUD | 20.93% |
| 2006 | -9.94 Million AUD | -41577.15% |
| 2005 | 23.96 Thousand AUD | 901.77% |
| 2004 | -2989.00 AUD | 70.15% |
| 2003 | -10.01 Thousand AUD | 99.68% |
| 2002 | -3.14 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.23 Million AUD | 0.0% |
| 2024 FY | -5.8 Million AUD | -659.16% |
| 2024 Q4 | -2.56 Million AUD | 0.0% |
| 2023 FY | -764 Thousand AUD | 92.23% |
| 2023 Q2 | -3.29 Million AUD | 0.0% |
| 2023 Q4 | 2.53 Million AUD | 0.0% |
| 2022 Q4 | -4.36 Million AUD | 0.0% |
| 2022 Q2 | -5.47 Million AUD | 0.0% |
| 2022 FY | -9.83 Million AUD | 22.13% |
| 2021 Q2 | -7.78 Million AUD | 0.0% |
| 2021 Q4 | -4.84 Million AUD | 0.0% |
| 2021 FY | -12.62 Million AUD | -33.34% |
| 2020 FY | -9.47 Million AUD | -13.77% |
| 2020 Q4 | -3.03 Million AUD | 0.0% |
| 2020 Q2 | -6.43 Million AUD | 0.0% |
| 2019 Q2 | -3.53 Million AUD | 0.0% |
| 2019 Q4 | -4.78 Million AUD | 0.0% |
| 2019 FY | -8.32 Million AUD | 41.3% |
| 2018 Q2 | -8.69 Million AUD | 0.0% |
| 2018 FY | -14.18 Million AUD | -5736.21% |
| 2018 Q4 | -5.48 Million AUD | 0.0% |
| 2017 Q2 | 6.32 Million AUD | 0.0% |
| 2017 FY | -243 Thousand AUD | -101.87% |
| 2017 Q4 | -6.56 Million AUD | 0.0% |
| 2016 FY | 12.98 Million AUD | 16.63% |
| 2016 Q2 | 9.74 Million AUD | 0.0% |
| 2016 Q4 | 3.23 Million AUD | 0.0% |
| 2015 Q2 | 7.01 Million AUD | 0.0% |
| 2015 Q4 | 4.11 Million AUD | 0.0% |
| 2015 FY | 11.13 Million AUD | -60.21% |
| 2014 FY | 27.97 Million AUD | 303.84% |
| 2014 Q4 | 3.38 Million AUD | 0.0% |
| 2014 Q2 | 24.59 Million AUD | 0.0% |
| 2013 FY | 6.92 Million AUD | -6.29% |
| 2013 Q4 | 5.11 Million AUD | 0.0% |
| 2013 Q2 | 1.81 Million AUD | 0.0% |
| 2012 Q3 | 1.84 Million AUD | 0.0% |
| 2012 FY | 7.39 Million AUD | -87.07% |
| 2012 Q2 | 1.84 Million AUD | -87.07% |
| 2012 Q1 | 14.28 Million AUD | 0.0% |
| 2012 Q4 | - AUD | -100.0% |
| 2011 Q4 | - AUD | -100.0% |
| 2011 FY | 57.14 Million AUD | 22.76% |
| 2011 Q1 | 11.63 Million AUD | 0.0% |
| 2011 Q2 | 14.28 Million AUD | 22.76% |
| 2011 Q3 | 14.28 Million AUD | 0.0% |
| 2010 Q4 | - AUD | -100.0% |
| 2010 Q1 | -1.92 Million AUD | 0.0% |
| 2010 Q2 | 11.63 Million AUD | 703.34% |
| 2010 Q3 | 11.63 Million AUD | 0.0% |
| 2010 FY | 46.55 Million AUD | 703.34% |
| 2009 Q1 | -1.25 Million AUD | 0.0% |
| 2009 FY | -7.71 Million AUD | -53.52% |
| 2009 Q2 | -1.92 Million AUD | -53.52% |
| 2009 Q4 | - AUD | 100.0% |
| 2009 Q3 | -1.92 Million AUD | 0.0% |
| 2008 Q4 | - AUD | 100.0% |
| 2008 Q2 | -1.25 Million AUD | 36.06% |
| 2008 Q1 | -1.96 Million AUD | 0.0% |
| 2008 FY | -5.02 Million AUD | 36.06% |
| 2008 Q3 | -1.25 Million AUD | 0.0% |
| 2007 Q4 | - AUD | 100.0% |
| 2007 Q2 | -1.96 Million AUD | 20.93% |
| 2007 Q1 | -2.48 Million AUD | 0.0% |
| 2007 Q3 | -1.96 Million AUD | 0.0% |
| 2007 FY | -7.86 Million AUD | 20.93% |
| 2006 Q1 | 5991.25 AUD | 0.0% |
| 2006 Q4 | - AUD | 100.0% |
| 2006 Q3 | -2.48 Million AUD | 0.0% |
| 2006 FY | -9.94 Million AUD | -41577.15% |
| 2006 Q2 | -2.48 Million AUD | -41577.15% |
| 2005 Q3 | 5991.25 AUD | 0.0% |
| 2005 Q4 | - AUD | -100.0% |
| 2005 FY | 23.96 Thousand AUD | 901.77% |
| 2005 Q1 | 747.25 AUD | 0.0% |
| 2005 Q2 | 5991.25 AUD | 701.77% |
| 2004 Q2 | 747.25 AUD | 129.85% |
| 2004 Q3 | 747.25 AUD | 0.0% |
| 2004 Q4 | - AUD | -100.0% |
| 2004 FY | -2989.00 AUD | 70.15% |
| 2004 Q1 | -2503.75 AUD | 0.0% |
| 2003 Q4 | -2503.75 AUD | 0.0% |
| 2003 FY | -10.01 Thousand AUD | 99.68% |
| 2003 Q2 | -2503.75 AUD | 99.68% |
| 2003 Q3 | -2503.75 AUD | 0.0% |
| 2003 Q1 | -786.19 Thousand AUD | 0.0% |
| 2002 Q3 | -786.19 Thousand AUD | 0.0% |
| 2002 Q2 | -786.19 Thousand AUD | 0.0% |
| 2002 Q4 | -786.19 Thousand AUD | 0.0% |
| 2002 FY | -3.14 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 183.28% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -299.658% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 84.14% |
| Biome Australia Limited | -1.67 Million AUD | -247.263% |
| Patrys Limited | -3.53 Million AUD | -63.881% |
| Orthocell Limited | -7.18 Million AUD | 19.231% |
| Imugene Limited | -149.68 Million AUD | 96.125% |
| Noxopharm Limited | -3.57 Million AUD | -62.096% |
| PYC Therapeutics Limited | -37.72 Million AUD | 84.626% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 53.711% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 29.595% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 9.037% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 40.481% |
| CSL Limited | 2.64 Billion AUD | 100.22% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 33.684% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -140.746% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 116.276% |
| Starpharma Holdings Limited | -8.16 Million AUD | 28.965% |
| Nanollose Limited | -1.15 Million AUD | -401.49% |
| Memphasys Limited | -4.44 Million AUD | -30.571% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -253.269% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 1888.964% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -28.79% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 58.182% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -102.491% |
| Race Oncology Limited | -13.81 Million AUD | 58.03% |
| Nyrada Inc. | -1.38 Million AUD | -318.402% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 211.303% |
| Dimerix Limited | -17.07 Million AUD | 66.032% |
| PharmAust Limited | -9.03 Million AUD | 35.786% |
| Immutep Limited | -39.89 Million AUD | 85.462% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 86.296% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 69.671% |
| BTC Health Limited | 1.05 Million AUD | 649.614% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 103.692% |
| Biotron Limited | -3.43 Million AUD | -68.775% |
| Tissue Repair Ltd | -4.13 Million AUD | -40.161% |
| AdAlta Limited | -5.38 Million AUD | -7.781% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 87.904% |
| Hexima Limited | -933.87 Thousand AUD | -521.069% |
| AnteoTech Limited | -8.88 Million AUD | 34.688% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 90.111% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 67.161% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -68.773% |
| Actinogen Medical Limited | -13.04 Million AUD | 55.536% |
| Immuron Limited | -6.93 Million AUD | 16.39% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -5.849% |